About ReCode Therapeutics ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNP platform to target organs and tissues beyond . The Company's pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic . Dr. Dale Bredesen's 30+ years of research in Neurodegeneration has proven that Alzheimer's is essentially caused by "36 holes in the roof" of your brain, meaning, there are 36 perpetrators and likely many more that lead to the diagnosis of cognitive decline, and eventually Alzheimer's disease. ReCode Therapeutics is a biopharmaceutical company powering the next wave of genetic medicines through superior delivery. Jan 10, 2022, 10:26am EST. Find company research, competitor information, contact details & financial data for Recode Therapeutics, Inc. of Dallas, TX. The number of employees ranges from 1 to 25. Type: Company - Private. ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode Therapeutics, a US-based genetic medicines spinout of University of Texas Southwestern Medical Center, picked up another $120m in series B financing yesterday to bring the round's total to $200m. ET on Thursday, September 29, 2022 cookielawinfo-checkbox-advertisement. Industry: Biotech & Pharmaceuticals. The presentation will be made available on the ECFS website for viewing at the start of the presentation on June 11, 2021 at 9:00 a.m. CET (3:00 a.m. EST). The startup's technology uses lipid nanoparticles to deliver genetic medicines . "Founded in 2015, ReCode Therapeutics is a multi-platform company developing 1) non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues and 2) first-in-class tRNA NanoCorrectors. Recode Biosciences was founded with the singular mission of discovering novel mechanisms to reprogram adult differentiated cells into alternate cells of desired lineage and functional capacity for potential therapeutic use. S72 Business Portraits. Our focus is to develop viable, efficient and effective alternatives to embryonic stem cells for therapeutic benefit. Understand laboratory supply streams, waste streams, and have experience working in an R&D laboratory environment. Recode Therapeutics corporate office is located in 1455 Adams Drive, Suite 1120, Menlo Park, California, United States and has 34 employees. Web Traffic by SEMrush. Rare Diseases. Its headquarters is located at Menlo Park, California, USA. ReCode has developed a non-viral . ReCode Therapeutics, which has operations in Dallas and Menlo Park, Calif., announced the investment Thursday that was led by Pfizer's venture capital unit and San Francisco-based EcoR1 Capital . The position of the President & CEO is occupied by David J. Lockhart. ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics will present a corporate overview on Friday, June 10th from 11:00 - 11:25 a.m. At ReCode, we bring a unique blend of rigor, creativity, and curiosity to our high-hurdle mission: harnessing our multi-platform approach to develop disease-modifying medicines. menlo park, calif. and dallas, texas - june 14, 2021 - recode therapeutics (the "company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its sort-lnptm platform for the treatment of life-limiting respiratory diseases, today announced that the company will participate in two upcoming virtual investor conferences ReCode's selective organ targeting (SORT) lipid . 6/3/2022. Monthly Visits Growth -59.98%. Mission: We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode Therapeutics is a biopharmaceutical company powering the next wave of genetic medicines through superior delivery. Website: ReCode Therapeutics. ReCode Therapeutics names its CEO. 2015. Vox's Recode explores how the digital world is changing from keeping Big Tech accountable to explaining how decisions in Silicon Valley affect your daily life. MENLO PARK, Calif. & DALLAS, September 22, 2022--ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit at 8:00 a.m. ReCode Therapeutics (www.recodetx.com) offers a competitive compensation/benefits package . ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP . MENLO PARK, Calif. & DALLAS, September 12, 2022--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced . With the additional $120M in new financing, the company has secured a total of $200M in Series B funding. ReCode's diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). The company focuses on the treatment of cystic fibrosis (CF . The company received . recode therapeutics. ReCode Therapeutics is a small health care company based in Menlo Park, CA with only 94 employees and an annual revenue of $2.2M. See insights on PTC Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Respiratory. Traffic. ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data . ReCode is an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. ReCode Therapeutics attracts $120 million in new investment for its drug delivery tech The 7-year-old company uses technology developed by co-founder Daniel J. Seigwart of UT Southwestern's Simmons. ARRAffinity cookie is set by Azure app service, and allows the service to choose the right instance established by a user to deliver subsequent requests made by that user. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and . June 29, 2022 By Sean Whooley ReCode Therapeutics announced today that it closed a Series B extension financing round, adding $120 million in new funds. ReCode's selective organ targeting (SORT) lipid . menlo park, calif. & dallas, jun 11, 2021 -- ( business wire )-- recode therapeutics (the "company"), a biopharmaceutical company pioneering disease-modifying medicines for the treatment of. Gene correction and mRNA company ReCode Therapeutics has announced the close of a Series B extension financing round. Description. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with. Jul 22, 2022. Monthly Visits 1,448. MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNP TM platform, today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm . ReCode's selective organ targeting (SORT) lipid. Get the latest business insights from Dun & Bradstreet. ReCode Therapeutics is a private company that has been in the industry for 6 years. An archived replay of the presentation will be made available on the Company's website following the presentation. Business Area (s): Personalized Medicine. ReCode's selective organ targeting (SORT) lipid . ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target or gans and tissues beyond the liver. The company is headquartered in Dallas, Texas and Menlo Park, California. Engagement. ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation LNP delivery technology to target organs and tissues beyond the liver. ReCode's selective organ targeting (SORT) lipid . recode therapeutics inc. recode therapeutics , inc. Suliman, former president and chief operating officer of San Francisco-based Alector, an immuno-neurology and immuno-oncology company, is taking the helm as CEO at Dallas-founded ReCode Therapeutics. Menlo Park, Calif. and Dallas, Texas - September 3, 2021 - ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences in September: Workers in a lab at ReCode Therapeutics, a biopharma company that got its start in a research project at the University of Texas Southwestern. The ReCODE Program is intended for individuals who are currently experiencing symptoms of cognitive decline and are ready to engage in an intensive program to restore and enhance cognitive function while promoting overall health. ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. Competitors: Unknown. Drug Discovery Drug Delivery Financing GEN Edge Therapeutics Respiratory Drugs SORTing It Out: ReCode Expands Beyond Respiratory Disorders Developer of lipid nanoparticle-based mRNA and gene. ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today presented encouraging . Shehnaaz Suliman, chief executive of Dallas-based ReCode Therapeutics, is among 71 female biotech CEOs authoring a letter to elected officials and lawmakers that condemns the U.S. Supreme Court . ReCode is taking this concept to the next level with our SORT LNP technology that can deliver a wide variety of genetic medicines, each one safely packaged in novel lipid carriers designed to reach the target organs and cells throughout the body that need treatment." Dan Siegwart, Ph.D., ReCode Co-Founder Our Story Begins with Pioneering Research Our novel mRNA and gene correction therapeutics have the potential to make this a reality. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. MENLO PARK, Calif. & DALLAS, October 21, 2021 -- ( BUSINESS WIRE )-- ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its. The SORT LNP platform is the foundation for ReCode's . Report incorrect company information. The Company's pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. Company ReCode Therapeutics Website https://recodetx.com/ Headquarter United States Employee N/A Founded in 2015 Industry Biotechnology Speciality RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, Biotechnology Departments The. Blogs. ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNP platform to target organs and tissues beyond the liver. 1 year. ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapeutics using its powerful, proprietary SORT-LNP TM platform to target organs and tissues beyond the liver. PTC Therapeutics has 4 employees at their 1 location and $538.59 m in annual revenue in FY 2021. ARRAffinity. Menlo Park, California-based ReCode, which develops the selective organ targeting (SORT) lipid nanoparticle technology (LNP) delivery platform, has now raised $200 million total in the Series B. Industry Health Care Revenue $2.2M Employees 94 Founded in 2015 Headquarters Menlo Park, CA Website www.recoderx.com Organization Type Private Is This Your Company? The abstract will be available on the ECFS website beginning on Wednesday, June 2, 2021. Presenter: Michael Torres, Ph.D., Vice President, R&D, ReCode Therapeutics. Find company research, competitor information, contact details & financial data for Recode Therapeutics, Inc. of Menlo Park, CA. Dallas Biopharma Adds $120M to Series B Raise. ReCode Therapeutics - Powering the future of genetic medicines through superior delivery Powering the next wave of genetic medicines through superior delivery Groundbreaking Technology First genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver Precision Genetic Medicines Description: ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. Global Trikafta Market Analysis Report 2021-2028 Featuring Vertex Pharmaceuticals, Eloxx, Recode Therapeutics and Corbus. Vertex to Announce Second Quarter 2022 Financial Results on August 4. session. 1+ years of proven success guiding teams for lab operations staff and vendors. Revenue: Unknown / Non-Applicable. menlo park, calif. & dallas-- ( business wire )-- recode therapeutics (the "company"), a biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today presented encouraging preclinical data from the company's rna-based molecular therapy program for cystic fibrosis (cf) delivered The company currently specializes in the Biotechnology, Biotechnology areas. <p>Breath Therapeutics is a biotechnology company focused on the development of aerosolized drugs to improve the treatment of rare and life-threatening pulmonary diseases. The Company develops the first therapy for treatment of Bronchiolitis Obliterans, which is a life-threatening lung disease without approved drug therapy.<br><br></p> ReCODE is the only clinically proven program to reverse cognitive decline in early-stage Alzheimer's disease. Claim This Company Page Get the latest business insights from Dun & Bradstreet. ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors.